Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,814 DKK | -0.78% |
|
+2.49% | -16.06% |
01:27pm | Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex | MT |
07-15 | RBC Capital Upgrades Genmab to Outperform | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.06% | 16.92B | |
+20.17% | 126B | |
+24.67% | 118B | |
+24.05% | 27.87B | |
-17.74% | 20.95B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B | |
+151.63% | 12.57B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Announces Sales Results of DARZALEX (daratumumab) for 2017